Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

The Role of Heterotypic DENV-specific CD8+T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection.

Talarico LB, Batalle JP, Byrne AB, Brahamian JM, Ferretti A, García AG, Mauri A, Simonetto C, Hijano DR, Lawrence A, Acosta PL, Caballero MT, Paredes Rojas Y, Ibañez LI, Melendi GA, Rey FA, Damonte EB, Harris E, Polack FP.

EBioMedicine. 2017 Jun;20:202-216. doi: 10.1016/j.ebiom.2017.04.033. Epub 2017 Apr 27.

2.

Salmonella Typhi Porins OmpC and OmpF Are Potent Adjuvants for T-Dependent and T-Independent Antigens.

Pérez-Toledo M, Valero-Pacheco N, Pastelin-Palacios R, Gil-Cruz C, Perez-Shibayama C, Moreno-Eutimio MA, Becker I, Pérez-Tapia SM, Arriaga-Pizano L, Cunningham AF, Isibasi A, Bonifaz LC, López-Macías C.

Front Immunol. 2017 Mar 9;8:230. doi: 10.3389/fimmu.2017.00230. eCollection 2017.

3.

CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lungs.

Zhang L, Li H, Hai Y, Yin W, Li W, Zheng B, Du X, Li N, Zhang Z, Deng Y, Zeng R, Wei L.

J Virol. 2017 Apr 28;91(10). pii: e02111-16. doi: 10.1128/JVI.02111-16. Print 2017 May 15.

PMID:
28275186
4.

Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age.

Jans J, Wicht O, Widjaja I, Ahout IM, de Groot R, Guichelaar T, Luytjes W, de Jonge MI, de Haan CA, Ferwerda G.

PLoS One. 2017 Jan 30;12(1):e0170877. doi: 10.1371/journal.pone.0170877. eCollection 2017.

5.

Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.

Jounai N, Yoshioka M, Tozuka M, Inoue K, Oka T, Miyaji K, Ishida K, Kawai N, Ikematsu H, Kawakami C, Shimizu H, Mori M, Ishii KJ, Takeshita F.

EBioMedicine. 2017 Feb;16:124-135. doi: 10.1016/j.ebiom.2017.01.014. Epub 2017 Jan 16.

6.

Animal models of respiratory syncytial virus infection.

Taylor G.

Vaccine. 2017 Jan 11;35(3):469-480. doi: 10.1016/j.vaccine.2016.11.054. Epub 2016 Nov 29.

7.

Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Griffiths C, Drews SJ, Marchant DJ.

Clin Microbiol Rev. 2017 Jan;30(1):277-319. Review.

PMID:
27903593
8.

Enterovirus D-68 Infection, Prophylaxis, and Vaccination in a Novel Permissive Animal Model, the Cotton Rat (Sigmodon hispidus).

Patel MC, Wang W, Pletneva LM, Rajagopala SV, Tan Y, Hartert TV, Boukhvalova MS, Vogel SN, Das SR, Blanco JC.

PLoS One. 2016 Nov 4;11(11):e0166336. doi: 10.1371/journal.pone.0166336. eCollection 2016.

9.

Metabolic pathways of lung inflammation revealed by high-resolution metabolomics (HRM) of H1N1 influenza virus infection in mice.

Chandler JD, Hu X, Ko EJ, Park S, Lee YT, Orr M, Fernandes J, Uppal K, Kang SM, Jones DP, Go YM.

Am J Physiol Regul Integr Comp Physiol. 2016 Nov 1;311(5):R906-R916. doi: 10.1152/ajpregu.00298.2016. Epub 2016 Aug 24.

PMID:
27558316
10.

Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin.

Luo Q, Vickers TJ, Fleckenstein JM.

Clin Vaccine Immunol. 2016 Jul 5;23(7):628-37. doi: 10.1128/CVI.00248-16. Print 2016 Jul.

11.
12.

Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.

Widjaja I, Wicht O, Luytjes W, Leenhouts K, Rottier PJ, van Kuppeveld FJ, Haijema BJ, de Haan CA.

J Virol. 2016 Jun 10;90(13):5965-77. doi: 10.1128/JVI.00235-16. Print 2016 Jul 1.

13.

Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.

Palomo C, Mas V, Thom M, Vázquez M, Cano O, Terrón MC, Luque D, Taylor G, Melero JA.

J Virol. 2016 May 12;90(11):5485-98. doi: 10.1128/JVI.00338-16. Print 2016 Jun 1.

14.

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease.

Acosta PL, Caballero MT, Polack FP.

Clin Vaccine Immunol. 2015 Dec 16;23(3):189-95. doi: 10.1128/CVI.00609-15. Review.

15.

Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin.

Lee YN, Hwang HS, Kim MC, Lee YT, Kim YJ, Lee FE, Kang SM.

Nanomedicine. 2016 Apr;12(3):759-70. doi: 10.1016/j.nano.2015.11.007. Epub 2015 Dec 2.

16.

Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.

Cullen LM, Blanco JC, Morrison TG.

J Transl Med. 2015 Nov 5;13:350. doi: 10.1186/s12967-015-0705-8.

17.

Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells.

Kim KH, Lee YT, Hwang HS, Kwon YM, Jung YJ, Lee Y, Lee JS, Lee YN, Park S, Kang SM.

PLoS One. 2015 Oct 15;10(10):e0139916. doi: 10.1371/journal.pone.0139916. eCollection 2015.

18.

Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Bergmann-Leitner ES, Leitner WW.

Vaccines (Basel). 2014 Apr 10;2(2):252-96. doi: 10.3390/vaccines2020252. Review.

19.

Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.

O'Konek JJ, Makidon PE, Landers JJ, Cao Z, Malinczak CA, Pannu J, Sun J, Bitko V, Ciotti S, Hamouda T, Wojcinski ZW, Lukacs NW, Fattom A, Baker JR Jr.

Hum Vaccin Immunother. 2015;11(12):2904-12. doi: 10.1080/21645515.2015.1075680.

20.

Proteomic contributions to our understanding of vaccine and immune responses.

Galassie AC, Link AJ.

Proteomics Clin Appl. 2015 Dec;9(11-12):972-89. doi: 10.1002/prca.201500054. Epub 2015 Sep 10. Review.

Supplemental Content

Support Center